Grifols | GRFS - Interest Expense On Debt


Grifols reported EUR156.07M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Alaunos Therapeutics USD 0 0 Dec/2023
Arca Biopharma USD 0 0 Mar/2025
Capricor Therapeutics 581K 581K Dec/2024
Cara Therapeutics 43.75M 4.8M Jun/2025
Esperion Therapeutics USD 15.08M 1.36M Sep/2024
GlaxoSmithKline GBP 188M 21M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Immunic 400K 400K Dec/2024
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 6.02M 420K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
TherapeuticsMD USD 20K 25K Sep/2023